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CardiomyopathyHeart failure (HF) occurs when the cardiac output, no longer compensated by endogenous mechanisms, fails to
meet the metabolic demands of the body. In most populations, the prevalence of heart failure continues to rise,
constituting amajor public health burden, especially in developed countries. There is some evidence that the risk
of HF in the general population depends on genetic predisposition, necessarily characterised by a very complex
architecture. In a small, but probably underestimated proportion, HF is caused by Mendelian inherited forms of
myocardial disease. The genetic background of these genetic conditions is a matter of intensive research that is
already shedding light onto the genetics of common sporadic forms of HF. In this review, we brieﬂy review the
insights provided by candidate gene and genome-wide association approaches in common HF and then describe
the main genetic causes of inherited heart muscle disease. Finally we present the current challenges and future
research needs for both forms of HF. This article is part of a Special Issue entitled: Heart failure pathogenesis and
emerging diagnostic and therapeutic interventions.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Heart failure (HF) occurs when the cardiac output, no longer com-
pensated by endogenous mechanisms, fails to meet the metabolic
demands of the body. Clinically, it is deﬁned [1–3] as a syndrome
characterised by symptoms of breathlessness, fatigue, signs of ﬂuid
retention and a cardiac structural abnormality. Its prevalence is growing
in developed and emerging countries as a result of population aging, the
successful management of coronary artery disease and an increasing
prevalence of diabetes and hypertension. At 40 years of age, the lifetime
risk of developing HF for men and women is 20%, with a prevalence of
2–4% individuals in Europe and the USA. The prognosis remains poor,
with a reported 50% survival four years after diagnosis [1,4–6].
Whilst most cases of HF are caused by coronary artery disease,
hypertension, diabetes and valvular heart disease [1], epidemiological
studies suggest that, even in these acquired disorders, the risk of HF
depends to some extent on genetic predisposition. In the Framingham
cohort [7], the relative risk of developing HF is 1.69 if one parent is
affected and 1.92 if both parents have HF. These acquired forms of HF
are themselves characterised by a very complex genetic architecture
(Fig. 1) that includes the predisposition for the individual conditions
themselves, genetic variation that modulates the maladaptive patho-
physiological response to pathophysiological stressors, and genetic
modiﬁers of the response to therapy. Not surprisingly, studies ofure pathogenesis and emerging
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poorly reproducible or only modest effect size.
In a small but important proportion of cases, HF is caused by Men-
delian genetic disorders. The various clinical phenotypes are classiﬁed
according to ventricular morphology and function into hypertrophic,
dilated, restrictive, arrhythmogenic and unclassiﬁed cardiomyopa-
thies [8]. They are mostly inherited as autosomal dominant traits,
characterised by locus and allelic heterogeneity and highly variable
intra- and interfamilial expressivity with incomplete/age-related
clinical penetrance [8,9]. The highly variable expressivity and pene-
trance may be explained by modiﬁer genes, epigenetic effects, post-
transcriptional and post-translational modiﬁcations, and environmen-
tal effects [10,11]. The complexity and clinical heterogeneity of genetic
heart muscle disease has challenged the understanding of the geno-
type–phenotype relationships but is a matter of intensive research
that is shedding light on all forms of heart failure.
2. Genetics of acquired forms of heart failure
2.1. Neurohormonal activation — candidate gene studies
The maladaptive activation of adrenergic pathways and the renin–
angiotensin–aldosterone system that perpetuate injury independently
of the initial aetiology is well described. Similarly, the clinical beneﬁts of
beta-blockers and angiotensin-converting enzyme (ACE) inhibitors are
established [1,2,12]. Numerous candidate gene studies examining dif-
ferent molecular components of the neurohumoral system and their
impact on response to therapy have been published. In most cases,
data supporting an inﬂuence of particular polymorphisms on the course
of the disease are inconsistent or lack sufﬁcient power. Nevertheless,
Fig. 1. The complex genetic architecture of common/acquired heart failure.
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support a role for common polymorphisms on disease progression.
2.1.1. Adrenergic pathway polymorphisms
2.1.1.1. β -1 adrenergic receptor. The predominant beta-adrenergic
receptor in the heart is the β-1 receptor (ADRB1) [13]. ß-1 receptors
mediate the chronotropic, inotropic and lusitropic effects of catechol-
amines and various candidate gene studies have analysed the possible
effects of common beta-1 adrenoreceptor polymorphisms as modiﬁers
of heart failure risk and prognosis [13]. The more consistent and repro-
ducible associations involve the Arg389Gly polymorphism (rs1801253,
MAF=0,304) [14], occurring in a highly conserved position.Mechanistic
studies [15–21] have demonstrated that the Arg389 allele is charac-
terised by increased adenylyl cyclase signalling, enhanced inotropy
and an increased susceptibility to beta-blockers. In contrast, the Gly389
allele is characterised by decreased inotropy and reduced sensitivity to
beta-blockers.
Clinical studies have suggested a beneﬁcial effect of Arg389homozy-
gosity on exercise capacity and peak oxygen consumption [22,23] as
well as an enhanced therapeutic response to metoprolol [24,25] and
carvedilol [26] in the presence of the allele, either in heterozygosity or
homozygosity. A recent study investigating the combination of the
Arg389Gly polymorphism in the ADRB1 gene and the Gln27Glu poly-
morphism (rs1042714, MAF=0,234) in the adrenergic β(2)-receptor
gene (ADRB2) found that the combination was associated with a two-
fold increase in mortality relative to all other genotype combinations
inHFpatients treatedwith carvedilol. Therewas no difference in survival
in metoprolol-treated HF patients between genotype groups [27]. If
conﬁrmed in larger studies, this suggests a role of beta-adrenergic
genotyping in choosing therapeutic options in HF.
2.1.1.2. G protein-coupled receptor kinases.Myocardial β-adrenergic re-
ceptor down-regulation and desensitisation is mediated by G protein-
coupled receptor kinases (GRKs). The hypothesis that gain-of-function
genetic variation could be responsible for desensitisation and protec-
tion against the hyperactive adrenergic system in HF and loss-of-
function for an increase in the risk for HF development and a worseprognosis has been studied in candidate gene approaches. The best
studied single nucleotide polymorphism (SNP) is Gln41Leu in GRK5
(rs17098707; MAF=0.087; 0.20 in individuals of African ancestry)
[14]. Mechanistic studies show that Leu41 allele increases desensi-
tisation [28,29] mimicking a beta-blockade effect. Two studies showed
improved transplant-free survival in individuals homozygous or het-
erozygous for this allele [30,31].
2.1.2. Renin–angiotensin–aldosterone system
2.1.2.1. Angiotensin converting enzyme insertion–deletion polymorphism.
The observation that angiotensin converting enzyme (ACE) levels are
characterised by familial clustering, led to the identiﬁcation of a com-
mon 287 bp insertion–deletion polymorphism located in intron 16 of
the ACE gene [32] that is responsible for approximately half of the var-
iation in ACE plasma levels. Homozygous carriers of two deletion alleles
(DD) have higher ACE levels and homozygous carriers of two insertion
alleles (II) have lower levels; heterozygotes (ID) have intermediate
enzyme levels [33]. Given its location in a non-coding region, this poly-
morphism is probably not directly responsible for the variation in ACE
plasma levels, but is considered to be in close linkage disequilibrium
with the genetic variation that is responsible for serum ACE levels at
the molecular level.
The most reproducible ﬁnding regarding this polymorphism is the
association between DD genotype and the progression of ischaemic or
nonischaemic heart failure, with decreased transplant-free survival
[34–38]. Some studies have also shown that patients with the DD geno-
type have the greatest beneﬁt from ACE inhibitor and beta-blocker
therapy [37,38] as well as a relationship between the DD genotype
and left ventricular hypertrophy (LVH) [39–47]. Nevertheless, these
case–control studies are characterised by small and heterogeneous
samples. A recent meta-analysis challenged the signiﬁcance of the
associations between this ACE polymorphism and risk of HF [48],
but another meta-analysis conﬁrmed the association between the
DD genotype and LVH [49].
A very recent paper by Kolder et al. [50] further explored the role
of renin–angiotensin–aldosterone system (RAAS) polymorphisms in
the phenotypic expression of hypertrophic cardiomyopathy (HCM).
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rs5186; CMA, rs1800875; AGT, rs699; and CYP11B2, rs1799998)
were analysed in subjects carrying truncating mutations in the
MYBPC3 gene and no major effects on the HCM phenotype were
observed.
2.2. Other genetic susceptibility loci — genome-wide association studies
Genome-wide association studies (GWAS) allow a high-throughput
and unbiased approach to the identiﬁcation of risk loci for common
diseases, because they do not assume an initial hypothesis for the loca-
tion of genetic variants that impact on a complex trait. Usingmicroarray
platforms consisting of millions of SNPs distributed along the genome,
this method typically identiﬁes common variants with small individual
effects [51,52].
In the HF arena, two recently published GWAS [53,54] using
>2.4 million SNPs in >20,000 subjects, associated two SNPs with
the development of heart failure: one involving the USP3 gene
(ubiquitin-speciﬁc protease) in individuals of European ancestry,
and the other the LRIG3 gene (leucine-rich, immunoglobulin like
domain) in individuals of African ancestry. A third SNP located in the
CMTM7 gene (CKLF-like MARVEL transmembrane domain containing
7) was associated with HF mortality. For all three SNPs the odds ratios
were around 1.5.
In a subgenome approach, using 50,000 SNPs in 2000 genes poten-
tially associated with cardiovascular disorders, another recent study
revealed an association between HF and the SNP rs1739843, located
in an intronic region of the HSPB7 gene, that encodes a heat shock
protein [55]. This ﬁnding was reproduced in a multicentre European
study [56]. Given the absence of apparently functional SNPs upon
resequencing of the HSPB7 gene (all variants were synonymous or
intronic) and due to the fact that this gene is in high linkage disequi-
librium with CLCNKA (renal ClC-Ka chloride channel), also located at
1p36, Cappola et al. [57] resequenced the latter gene and found a sig-
niﬁcant association with HF for a missense variant, Arg83Gly, with an
odds ratio of 1.27 per allele copy. This means that the risk is increased
by 54% in homozygotes. Importantly, one quarter of Caucasians are
homozygotes.
Finally, a European consortium study on dilated cardiomyopathy
(DCM) [58] identiﬁed three DCM-associated SNPs. Two of these,
rs10927875 and rs2234962, were replicated in independent samples
(1165 DCM patients and 1302 controls), with p-values of 0.002 and
0.009, respectively. rs10927875 maps to a region on chromosome
1p36.13 which encompasses several genes, including HSPB7. The
second identiﬁed locus involves rs2234962, a non-synonymous SNP
(c.T757C, p. C151R) located within the coding sequence of BAG3
(BCL2-associated athanogene 3) on chromosome 10q26. The authors
also identiﬁed rare variants in this gene, which segregated in families
with familial dilated cardiomyopathy. This is in keeping with another
recent study by Norton et al. [59] which used GWAS of copy number
variation and whole-exome sequencing, and identiﬁed rare variants
in BAG3 as a cause for familial dilated cardiomyopathy. This is one
of the rare examples of the same genetic locus showing an association
between rare variants with large effect and rare familial monogenetic
disease and common variants with small effects with sporadic com-
mon disease.
2.3. Genetic susceptibility loci for cardiovascular risk factors and
atherosclerotic heart disease
Several recent GWAS investigated genetic susceptibility for athero-
sclerotic disease and risk factors that are in turn important causes of
acquired heart failure. These studies were reviewed in two very recent
publications [60,61]. A large number of loci are associated with an in-
creased risk of coronary artery disease [62,63] or myocardial infarction
[64]. Other recently described loci confer increased susceptibility toestablished cardiovascular risk factors, such as high blood pressure
[65], dyslipidaemia [66] and diabetes [67,68].
2.4. Genetic susceptibility for myocarditis
A recent publication explored the role of DNA variation in toll-like
receptor 3 (TLR3) as a possible risk factor for myocarditis [69]. The
authors sequenced this gene in patients diagnosed with enteroviral
myocarditis and identiﬁed a rare variant (c.1660C3T, p.P554S) in one
patient with Coxsackievirus B3 myocarditis as well as an increased fre-
quency of a common polymorphism (rs3775291, c.1235C>T, p.L412F)
compared with controls. Expression of either variant resulted in signif-
icantly reduced TLR3-mediated signalling in in vitro studies, suggesting
a role for rare and common variation in innate immune response genes
as a mechanism for increased susceptibility to myocarditis.
3. Genetics of inherited heart failure
3.1. Dilated cardiomyopathy
Familial dilated cardiomyopathy (FDCM) is deﬁned as idiopathic
dilated cardiomyopathy (DCM) occurring in two ormore related family
members or in the presence of sudden death of a relative younger than
35 years of age [8,70]. Epidemiological studies using family history and
clinical, electrocardiographic and echocardiographic screening of ﬁrst
degree relatives have established the prevalence of FDCM as 20–50%
in idiopathic DCM cases [71–74]. This proportion varies depending on
the extent of family screening in different studies. A diversity of inheri-
tance patterns is recognised [75] with more than 80 reported genes
including those encoding sarcomere proteins, cytoskeleton and nuclear
envelope proteins and, more recently, membrane ion-channels and
desmosomes [76–78] (Table 1).
An identiﬁable genetic cause is present in around 25–30% of FDCM
cases [77]. Until very recently, LMNA was considered the most preva-
lent causal gene in FDCM, responsible for 4–8% of cases, but a new
study has found potentially disease-causing titin (TTN) truncating mu-
tations in 25% of patients with FDCM and 18 % of patients with sporadic
DCM [79]. Nevertheless, detection of LMNA variants are important as
they are an exception to almost all other genetic ﬁndings in patients
with cardiomyopathy which do not, for the moment, usually imply
any change in management. The presence of non-missense lamin
variants was recently conﬁrmed as a risk factor for malignant ventricu-
lar arrythmias in a multicentre study [80] and other studies have
shown that the presence of a lamin mutation is associated with a poor
prognosis [81,82] even in patients with mild dilation. Increased
arrhythmogenicity is also reported to be a feature of SCN5A (sodium
channel, voltage-gated, type V, alpha subunit) [83] and DCM associated
with desmosomal gene variants [78] but there is as yet no consensus on
the treatment of patients with such variants.
The genetic spectrumand heterogeneity of inherited DCMcontinues
to expand. In a very recent paper, genome-wide mapping and exome
sequencing in a unique family, where DCM segregated as an autosomal
recessive trait, were used to identify GATAD1 (GATA zinc ﬁnger
domain-containing protein 1) as a disease-causing gene for autosomal
recessive DCM [84]. It is likely that further mutations will continue to
emergewith the application of high throughput sequencing technology.
3.2. Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is deﬁned as left ventricular
hypertrophy (LVH) in the absence of abnormal loading conditions
sufﬁcient to explain the observed degree of hypertrophy. It has a popu-
lation prevalence of approximately 1 in every 500 adults and presents
with cardiovascular symptoms at any age [85,86]. Ventricular hypertro-
phy frequently develops during periods of rapid somatic growth, but
can appear de novo at any time from infancy to old age. Presentation
Table 1
Genes associated with dilated cardiomyopathy. Adapted with permission from [76].
Gene Protein OMIM % of familial
DCM cases
LMNA Lamin A/C 150330 6%
MYH7 β-myosin heavy chain 160760 4.2%
MYPN Myopalladin 608517 3.5%
TNNT2 Cardiac troponin T 191045 2.9%
SCN5A Sodium channel 600163 2.6%
MYBPC3 Myosin-binding protein C 600958 2%
RBM20 RNA binding protein 20 613171 1.9%
TMPO Thymopoietin 188380 1.1%
LAMA4 Laminin a-4 600133 1.1%
VCL Metavinculin 193065 1%
LDB3 Cypher/ZASP 605906 1%
TCAP Titin-cap or telethonin 604488 1%
PSEN1/2 Presenilin 1 / 2 104311/600759 1%
ACTN2 α-actinin-2 102573 0.9%
CRYAB Alpha B crystalin 123590 0.7%
TPM1 α-tropomyosin 191010 0.6%
ABCC9 SUR2A 601439 0.6%
ACTC1 Cardiac actin 102540 0.5%
PDLIM3 PDZ LIM domain protein 3 605889 0.5%
ILK Integrin-linked kinase 602366 0.5%
TNNC1 Cardiac troponin C 191040 0.4%
TNNI3 Cardiac troponin I 191044 0.4%
PLN Phospholamban 172405 0.4%
DES desmin 125660 0.3%
SGCD δ-sarcoglycan 601411 0.3%
CSRP3 Muscle LIM protein 600824 0.3%
MYH6 α-myosin heavy chain 160710 Unknown
TTN Titin 188840 Unknown




DMD Dystrophin 300377 Unknown
GATAD1 GATA zinc ﬁnger domain
containing 1
614518 Unknown
BAG3 BCL2-associated athanogene 3 603883 Unknown
TAZ/G4.5 Tafazzin 300394 Unknown
Table 2
Genes associated with hypertrophic cardiomyopathy. Adapted from [132].
Gene Protein OMIM % of genotype-positive
cases





MYBPC3 Myosin-binding protein C,
cardiac-type
600958 40%
TNNT2 Troponin T, cardiac muscle 115195 5%
TNNI3 Troponin I, cardiac muscle 191044 5%
TPM1 Tropomyosin 1 alpha chain 115196
191010
2%






MYL3 Myosin light polypeptide 3 160790
608751
1%
ACTC1 Actin, alpha cardiac muscle 1 102540 Unknown
CSRP3 Cysteine and glycine-rich protein
3, muscle LIM protein
600824 Unknown
TTN Titin 188840 Unknown
ACTN2 Alpha-actinin-2 102573 Unknown
MYH6 Myosin heavy chain, cardiac
muscle alpha isoform
160710 Unknown
TCAP Telothonin 604488 Unknown
TNNC1 Troponin C, slow skeletal and cardiac
muscles
191040 Unknown
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thrive. In older children and adults the most common symptoms are
dyspnoea, syncope and chest pain. HCM is generally considered to be
the commonest cause of sudden cardiac death in individuals below
35 years of age with a peak incidence in adolescence and young
adulthood, often in minimally symptomatic individuals [87–89]. In
the long‐term, many patients develop progressive symptoms caused
by gradual deterioration in left ventricular function. This so‐called
“end‐stage” is characterised by severe impairment of contractile perfor-
mance and is associated with an annual mortality rate of 11% per year
from sudden ventricular arrhythmia, stroke and progressive diastolic
and systolic left ventricular failure [89].
HCM is often inherited as an autosomal dominant trait. Mutations
in cardiac sarcomere genes are found in approximately 60% of
patients with familial HCM and approximately 40% of patients with
unexplained LVH without a family history [90]. Since the identiﬁcation
of the ﬁrst cardiac disease-causing mutation in 1990, more than 900
mutations have been reported [91–96]. The majority affect cardiac
ß-myosin heavy chain (MYH7) and cardiac myosin binding protein C
(MYBPC3). Mutations in cardiac troponin T (TNNT2), troponin I
(TNNI3), alpha‐tropomyosin (TPM1), myosin light chains (MYL2,
MYL3) and cardiac actin (ACTC1) are also reported. Mutations in
other sarcomere or related genes, including alpha-myosin heavy chain
(MYH6), titin (TTN), Z‐disc protein genes such as muscle LIM protein
(CSRP3) or calcium-handling genes (e.g. phospholamban), individually
account for less than 1% of cases. A further 5% of adult and adolescent
patients with apparently unexplained left ventricular hypertrophy
have metabolic or storage disorders (e.g. Anderson–Fabry disease and
respiratory chain disorders), neuromuscular disorders, chromosome
abnormalities and genetic syndromes such as cardiofacial cutaneousdisorders. Table 2 shows the genes that have been associated with
hypertrophic cardiomyopathy. When all these disorders are excluded,
approximately 30–40% of familial cases remain genetically unexplained
[96].3.3. Left ventricular non-compaction
Left ventricular non-compaction (LVNC) of the myocardium is con-
sidered an unclassiﬁed cardiomyopathy in the European Society of
Cardiology (ESC) classiﬁcation scheme for heart muscle disease [8]. It
is characterised by prominent trabeculations and deep intertrabecular
recesses in association with a thin compacted epicardial muscle layer
[97,98]. In some patients, LVNC is associatedwith left ventricular dilata-
tion and systolic dysfunction. LVNC occurs in association with many
congenital cardiac disorders, but it is still not clear whether isolated
LVNC is a separate cardiomyopathy or a morphological trait shared by
phenotypically distinct cardiomyopathies. The prevalence of LVNC, esti-
mated from retrospective imaging studies, ranges from 4.5 to 26 per
10,000 adult patients [8]. Many patients are completely asymptomatic,
but some present with congestive heart failure, thromboembolism,
arrhythmias and sudden cardiac death.
Familial disease is estimated to occur in 18% to 50% of adults with
isolated LVNC, mostly with an autosomal dominant pattern of inher-
itance [99]. An exception is Barth syndrome, caused by Tafazzin gene
(G4.5 / TAZ) mutations that result in protein truncation, an X-linked
disorder that causes severe cardiolipin deﬁciency in the mitochondrial
membrane and that is clinically characterised by neutropenia and
LVNC [100].
In adult patients with LVNC, numerousmutations in genes encoding
sarcomere proteins have been reported. In 2008, using a panel of 6
sarcomere protein genes – MYH7, ACTC1, TNNT2, TNNI3, MYL2 and
MYL3 – Klaassen et al. [101] reported that LVNC was associated with
mutations in sarcomere genes (MYH7, TNNT2 and ACTC1) in 17% of
63 adult patients with LVNC. In a more recent study by Hoedemakers
et al. [102], variants in 11 genes were reported in 41% of 56 patients
with LVNC: 6 sarcomere protein, 2 calcium-handling genes and other
genes such as lamin A/C (LMNA), ZASP (LDB3), and Tafazzin (TAZ)
were implicated. The cardiological screening of relatives and themolec-
ular analysis of probands and relatives combined suggested that 67% of
LVNC is familial. HCM and DCMwere identiﬁed in 11 (34%) families.
Table 3
Genes associated with left ventricular non-compaction.
Gene Protein OMIM % of cases
MYH7 Myosin heavy chain, cardiac muscle beta isoform 160760
192600
Unknown
MYBPC3 Myosin-binding protein C, cardiac-type 600958 Unknown
TNNT2 Troponin T, cardiac muscle 115195 Unknown
TNNI3 Troponin I, cardiac muscle 191044 Unknown
TPM1 Tropomyosin 1 alpha chain 115196
191010
Unknown
ACTC1 Actin, alpha cardiac muscle 1 102540 Unknown
LDB3 Cypher/ZASP 605906 Unknown
LMNA Lamin A/C 150330 Unknown
TAZ/G4.5 Tafazzin 300394 Unknown
DTNA Dystrobrevin, alpha 601239 Unknown
CASQ2 Calsequestrin 114251 Unknown
Table 4
Genes associated with arrhythmogenic ventricular cardiomyopathy. Adapted from
[133].
Gene Protein OMIM % of cases
RYR2 Ryanodine receptor 2 180902 Rare
DSP Desmoplakin 125647 6%–16%
TMEM43 Transmembrane protein 43 612048 Unknown
PKP2 Plakophilin 2 602861 11%–43%
DSG2 Desmoglein 2 125671 12%-40%
DSC2 Desmocollin 2 125645 Rare
TGFB3 Transforming growth beta 3 190230 Rare
JUP Junction plakoglobin 173325 Rare
DES Desmin 125660 Unknown
TTN Titin 188840 Unknown
LMNA Lamin A/C 150330 Unknown
2455L.R. Lopes, P.M. Elliott / Biochimica et Biophysica Acta 1832 (2013) 2451–2461Finally, a recent paper extended these ﬁndings to an analysis of
disease penetrance and genotype–phenotype correlations in families
[103]. Eighteen mutations were identiﬁed in 29% of the probands.
Fifteen distinct heterozygous mutations were found in 5 sarcomere
protein genes: MYH7, MYBPC3, TPM1, ACTC1, and TNNT2. Mutations
occurred most frequently in MYH7 and MYBPC3 (13% and 8%, respec-
tively). Familial disease was present in 16 probands (25%), 8 of whom
were mutation-positive and 8 mutation-negative for sarcomere
genes. Despite the negative ﬁndings concerning the phenotypic com-
parison between mutation-positive and mutation-negative probands,
this study conﬁrmed sarcomere gene mutations as an important
cause of LVNC, present in nearly one third of the probands.
Table 3 summarises the main genes that have been associated
with left ventricular non-compaction.Table 5
Indications for genetic testing, according to the most recent guidelines. Adapted from [119]
myopathy, RCM: restrictive cardiomyopathy, ARVC: arrhythmogenic right ventricular cardiomy
[120].
Diagnosis (proband) Predictive testing
Indicated: rare or particular cardiomyopathy, especially
in the presence of atypical phenotypic features, in








• Associated with extracardiac manifestations: A
Not indicated: borderline or doubtful cardiomyopathy,
except selected cases in the setting of expert teams
after detailed clinical and family assessment
• asymptomatic relatives of a pati
when the disease-causing muta
characterized in the family (pro
• whether ‘familial’ or ‘sporadic’
questionable in sporadic DCM
in the presence of atypical asso
red-ﬂags)
• predictive diagnosis in children
age at which cardiac examinat
of age for most cardiomyopath3.4. Arrhythmogenic cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy (increasingly
designated arrhythmogenic cardiomyopathy (AVC) due to the recogni-
tion of biventricular and left-dominant forms) has an estimated preva-
lence of 1 in 1000 and is a major cause of sudden cardiac death in the
young [104]. It often presents with ventricular ectopy and ventricular
tachyarrhythmias, in the presence of a structurally normal heart or
only very mild changes in size and function of one or both ventricles.
Advanced disease is characterised by wall motion abnormalities, aneu-
rysms and severe dilatation of the right ventricle and left ventricular
dysfunction. The histopathological hallmark of the disease is ﬁbro-
fatty replacement of the myocardium.
As in other cardiomyopathies, there is high allelic heterogeneity,
extremely variable expressivity and incomplete penetrance. In most
patients the disease is inherited as an autosomal dominant trait
caused by mutations in ﬁve genes encoding desmosomal proteins
[105]: plakophilin-2 (PKP2), desmoplakin (DSP), plakoglobin (JUP),
desmoglein-2 (DSG2) and desmocollin-2 (DSC2) (Table 4). Non-
desmosomal genes implicated in the disease include the transforming
growth factor beta 3 (TGFB3), the cardiac ryanodine receptor 2
(RYR2) and the transmembrane protein 43 (TMEM43). Around 40% of
patients with AVC carry disease-causing or likely disease-causingmuta-
tions in the previously mentioned genes.
An autosomal recessive pattern of inheritance is observed in a rare
syndromic presentation [106], Naxos syndrome, characterised by a
triad of arrhythmogenic right ventricular cardiomyopathy, woolly
hair, and diffuse keratoderma over the pressure areas of the palms
and soles. Plakoglobin (JUP) is the causal gene and was the ﬁrst
AVC-associated gene described. A similar phenotype is described in
patients with homozygous mutations in desmoplakin [107].
An ARVC-like phenotype has also been described as part the het-
erogeneous spectrum of manifestations in patients with desmin
(DES)-related myopathy [108]. More recently, titin (TTN) mutations
were suggested to be an additional cause of ARVC [109]. A mutation
in the spring region demonstrated complete cosegregation in a large
family and reduced structural stability in functional studies. Finally in
a recent study, four ARVC probands without desmosomal mutations
were shown to carry lamin A/C variants, suggesting that rare variation
in this gene can be an additional cause of ARVC-like phenotypes [110].
Importantly, these lamin associated cases were characterised by con-
duction disease, a rare feature in patients with desmosomal variants.
3.5. Restrictive cardiomyopathy
Restrictive cardiomyopathy (RCM) is deﬁned phenotypically by
normal (or reduced) sized ventricles with bi-atrial enlargement andand [120], with permission. HCM: hypertrophic cardiomyopathy, DCM: dilated cardio-
opathy, LVNC: left ventricular non-compaction. Levels of evidence as per the original text
Prognosis
entwith a cardiomyopathy,
tion has been previously
band)
in HCM and ARVC, but
and sporadic RCM (except
ciated phenotype or
can be considered at the
ion is useful (10–12 years
ies).
Not indicated: genetic testing cannot be systematically
recommended for prognostic stratiﬁcation.
Indicated: should be considered in selected patients or for
selected types of cardiomyopathies, in the setting of expert
teams after detailed clinical and family assessment.
Table 6
Genetic overlap between different inherited cardiomyopathy phenotypes.
DCM HCM ARVC RCM LVNC
Sarcomere
ACTC1 X X X X
MYH7 X x X X
MYH6 x X
MYBPC3 X X X
TNNT2 X X X X
TNNI3 X X X
TNNC1 X X
TPM1 X X X
MYL2 X
MYL3 X x








Cytoskeleton and plasma membrane
DES X x x
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The main clinical manifestations are heart failure due to the diastolic
dysfunction, atrial arrhythmias and thromboembolism. As with all car-
diomyopathies, RCM can be a familial disease or an acquired condition,
often as part of a systemic disorder [10]. In familial disease, themajority
of described disease-causing mutations are located in the sarcomere
protein genes TNNI3, TNNT2, ACTC1 and MYL3 [111,112]. Additionally,
RCM can also be a manifestation of desmin-related cardiomyopathy,
caused my mutations in the desmin gene (DES), which should be
suspected in the presence of skeletal muscle symptoms and conduction
system disease [113].
4. Challenges and future research needs
4.1. Searching for the missing heritability in heart failure
The search for genetic loci that predispose to the development of
heart failure and that inﬂuence response to therapy and disease
progression has been dominated by two major study designs. The
ﬁrst, candidate gene studies, have focused mainly on genes likely to
be important in the pathophysiology of the heart failure syndrome
and molecular targets for commonly used drugs. The second approach,
genome-wide association studies, looks for associations between com-
mon variants and HF risk and prognosis at a population level using
array platforms containing million of SNPs [114]. Whilst the inﬂuence
of genetic background in heart failure is generally accepted, a limitation
of the data accrued so far has been their poor reproducibility and the
relatively small risk (usually b1.5-fold), associated with individual
variants. However, given the aetiological complexity of heart failure,
this is not particularly surprising (Fig. 1). [52,115–117]. A new approach
to the investigation of genetic determinants of heart failure may come
from the use of new high-throughput sequencing technologies [118]
that allow whole exome or genome sequencing of large populations.
Re-sequencing studies can directly identify millions of rare mutations
and may, therefore, be able to identify variants that are not tagged by
panels of common SNPs in patients with common HF [52]. High
throughput sequencing is already being applied to patients with
Mendelian forms of heart muscle disease as advances in massive paral-
lel sequencing technology permit sequencing of substantially larger
genomic regions at the same or lower cost compared to capillary Sanger
sequencing [118]. High-throughput sequencing (HTS) platforms facili-
tate the interrogation of many genes simultaneously making HTS the
ideal tool in the setting of inherited cardiomyopathy. The technique
can also be applied to study the effect of putative modiﬁer genes and
the effect of rare variants in large cohorts of patients with apparently
acquired forms of HF.
However, in the clinical context, the introduction of HTS approaches
also creates new challenges, particularly for whole-exome or genome
strategies. One of the greatest is that the majority of novel rare variants
identiﬁed using HTS are missense mutations that may or may not
be pathological. Proof of pathogenicity is classically supported by
co-segregation analysis, functional studies and the absence of the vari-
ant in normal controls. Nevertheless, application of all these methods
is challenging in a clinical setting because of the massive amounts of
sequencing information generated by HTS. There seems little doubt
that the translation ofHTS into clinical practicewill require thedevelop-
ment of new tools for discriminating disease-causing from benign
variation. These might include more sophisticated in silico prediction
models and the generation of large well-annotated disease-speciﬁc
databases that incorporate detailed clinical phenotyping.
4.2. Inherited heart failure: clinical application of genetic testing
In inherited heart muscle disease, clinical guidelines [119,120] rec-
ommend routine molecular genetic testing of the most clearly affected
member of the family. Given the high level of biological discriminationafforded by genetic testing, the ﬁnding of a potentially causal DNA
sequence variant theoretically supports the diagnosis but the most
important goal of genetic testing is to guide therapy and counselling
strategies for families [119,120]. Table 5 summarises the current indica-
tions for genetic testing, according to recent guidelines [119,120].
However, the use of genetic testing in everyday clinical practice is
challenging, for a number of reasons including the cost and complexity
of conventional sequencing technologies and the relatively low yield of
genetic testing which only results in the identiﬁcation of a causal vari-
ant in around 50% of familial HCM or ARVC cases and even less in famil-
ial DCM (20–30%).
A third factor that still hampers the use of genetics for clinical
decision-making is the poor understanding of genotype–phenotype
relationships. Many of the initial clinical associations established for
individual mutations are not reproducible [121–127]. An exception
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[96,128,129], especially in individuals with HCM and AVC (approxi-
mately 5 to 10% of patients). Patients carrying multiple variants tend
to present earlier and with more severe disease. A further recently
suggested genotype–phenotype association in HCM came from studies
that showed increased numbers of cardiovascular events andamore fre-
quent evolution to dilated phenotype in the presence of any sarcomere
gene mutation compared to genotype-negative patients [130,131].
However, this was not reproduced for LVNC, in another recent paper
exploring the same hypothesis [103].
Finally, it is increasingly recognised that the genetic background
of different inherited cardiomyopathies overlap substantially. This
further challenges current attempts to model genotype–phenotype re-
lationships. Widely different phenotypes (dilation, non-compaction,
and hypertrophy) can result from mutations in the same gene or even
from the same mutation. This genetic overlap is illustrated by Table 6.
How variation in one single gene can lead to different cardiomyopathy
phenotypes is not known but current hypotheses being investigated
include transcription regulation, post-translational modiﬁcations,
modiﬁer variants in other genes, environmental inﬂuences and the dif-
ferential effects of speciﬁc region/domain of the protein affected by the
mutation [10,11].
5. Conclusions. Translating new genetic insights into clinically
relevant data
As inherited cardiomyopathies constitute “naturally-occurring” HF
disease models, improved understanding of their genetic background
and genotype–phenotype relationshipsmay ultimately increase knowl-
edge of HF disease pathways and pathophysiology, and lead to develop-
ment of new therapies. For acquired and inherited forms of HF alike, a
better deﬁnition of the underlying common and rare genetic variation
will eventually promote to an era of personalised guidance, counselling
and therapeutic options. For these goals to be accomplished though,
further exploration of the molecular pathways (transcriptome and
proteome) that lead from rare and common genetic variation to a
ﬁnal cellular and organ-level phenotype (phenome) is required. At the
same time, an improved knowledge of the complex mechanisms of
gene expression regulation (e.g. miRNAs effects, DNA methylation,
and histone modiﬁcation) is crucial.
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